Codon

AUGUST 27, 2024

When doctors sequenced the DNA and RNA found in Alice’s blood and synovial fluid—the liquid that surrounds and lubricates joints—they found abnormally low levels of genes encoding iron-storing proteins and high levels of epidermal growth factor receptor RNA.

DNA 97

DNA Laboratories Hospitals Virus 97

Broad Institute

JANUARY 30, 2024

He has also emerged in recent years as a skilled and relatable science communicator, renowned for his efforts at Broad and beyond during the COVID-19 pandemic to unpack the fast-moving research on the new virus in an accessible way and give practical advice about masking, vaccines, and other public health measures.

Hospitals 137

Hospitals Virus Medical Schools Science 137

PLOS: DNA Science

JUNE 13, 2024

The virus SARS-CoV-2 emerged in Wuhan, home of a premiere research institute that focuses on viruses. An altered virus could have escaped. Evidence that the virus emerged, or escaped, from the wildlife trade is lacking. Her points: 1. Coincidence? I’ve never thought so. RaTG13 shares about 96.1%

Virus 52

Virus RNA DNA Science 52

Drug Target Review

JULY 5, 2023

In the study presented at ASGCT, what were the specific findings regarding the synergistic killing of SKOV3 ovarian tumour cells by the iPSC-derived lymphoid and myeloid cells? What are the key advancements in nucleic-acid delivery and targeted gene insertion that Eterna and Factor Bioscience presented at the ASGCT?

Therapies 103

Therapies DNA Engineering Virus 103

The Pharma Data

OCTOBER 23, 2020

14 in Infection Control & Hospital Epidemiology , updated recommendations are presented for the management of health care personnel (HCP) living with hepatitis and HIV. FRIDAY, Oct. 23, 2020 — In a Society for Healthcare Epidemiology of America white paper, published online Oct. Henderson, M.D.,

RNA 52

RNA Virus Vaccine Treatment 52

The Pharma Data

DECEMBER 3, 2020

Consequently, performing an immunoassay in the early stages of an infection will be negative because the antibodies cannot be produced yet, even though the disease is present. Sherlock Biosciences uses Cas13 to cut reporter RNA sequences after activation by guide RNA.

RNA 52

RNA Virus DNA Disease 52

The Pharma Data

MARCH 8, 2022

The virus carries the information to produce a series of proteins, capable of inhibiting antiviral recognition systems of the infected cell. Actually, these systems could identify viral genetic material (here: Ribonucleic acids/RNAs) and sound the alarm. Camouflage protects virus from immune system. Researchers led by Prof.

Clinical Pharmacology 52

Clinical Pharmacology Immune Response RNA Virus 52

Codon

SEPTEMBER 29, 2024

But, regardless of which was first, they all operated with the same core data as their mechanism for understanding life: messenger RNA ( mRNA ). Simple ones, but still… This presented the student with a tantalizing future: the ability to fully model how a cell reacted to genetic perturbations.

Engineering 141

Engineering Virus DNA Therapies 141

The Pharma Data

AUGUST 16, 2021

During challenge with the original SARS-CoV-2 virus, animals vaccinated with CV2CoV were found to be better protected based on highly effective clearance of the virus in the lungs and nasal passages. Clearance of the virus in the lungs and nasal passages of the animals was tested following challenge infection with the original virus.

Immune Response 52

Immune Response Vaccine Virus RNA 52

Drug Target Review

MAY 22, 2024

What are the key findings of Circio’s in vivo proof-of-concept for its circVec circular RNA platform technology compared to conventional mRNA-based expression with DNA vectors? Circular RNA (circRNA) has two major advantages versus mRNA in a vector-expression context.

Therapies 59

Therapies RNA Protein Expression DNA 59

Drug Target Review

SEPTEMBER 25, 2024

5 Here, the original oncogene is still present but the transdifferentiated cancer cells are less dependent on it. Investigating non-oncogene resistance as a parallel defense mechanism used by cancer cells to evade therapies could therefore present a significant opportunity to address drug resistance more comprehensively.

Small Molecule 105

Small Molecule Therapies Regulations Treatment 105

Drug Target Review

OCTOBER 2, 2024

RNA-based therapies, including mRNA and RNA interference (RNAi), are being explored to modulate gene expression in heart cells. Still, the high cost of CGTs, driven by their complexity and individualised nature, presents barriers to widespread adoption in cardiology, limiting patient access.

Therapies 98

Therapies Disease Engineering RNA 98

The Pharma Data

JULY 12, 2021

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced today the presentation of previously announced Phase 2 interim results from two Phase 2/3 clinical trials (MOVe-OUT and MOVe-IN) of molnupiravir (MK-4482/EIDD-2801), an investigational oral antiviral therapeutic. About Molnupiravir.

Clinical Trials 52

Clinical Trials Laboratories Research Laboratories RNA 52

The Pharma Data

SEPTEMBER 28, 2021

Acute respiratory infections are one of the leading causes of death and disability globally, presenting substantial health challenges especially for infants, the elderly and the immunocompromised. Roche is looking to expand availability of those tests beyond CE markets within the future.

Marketing 52

Marketing Virus DNA Disease 52

The Pharma Data

JULY 6, 2021

But HIV’s ability to mutate isn’t unique among RNA viruses – most viruses develop mutations, or changes in their genetic code, over time. Changes in mutationally constrained epitopes are rare, as they can cause the virus to lose its ability to infect and replicate, essentially rendering it unable to propagate itself.

Vaccine 52

Vaccine Virus Research Immune Response 52

Codon

JUNE 25, 2024

Proteins are colored blue and RNA molecules are colored orange and yellow. RNA and proteins comprise each ribosome, but the cell synthesizes these two biomolecules at different rates. Recall that a typical ribosome in bacteria is built from 50 proteins and 3 strands of RNA. The large and small ribosome subunits.

DNA 80

DNA RNA Laboratories Research 80

The Pharma Data

DECEMBER 16, 2020

Throughout the day, various presentations will be given by medical experts pertaining to Emergency Use Authorization (EUA). The Moderna vaccine is similar to Pfizer and BioNTech’s vaccine in the sense that they both use an approach utilizing messenger RNA (mRNA). The meeting is slated to run from 9 a.m. ET to 5:15 p.m.

Vaccine 52

Vaccine Immune Response FDA FDA Approval 52

The Pharma Data

MARCH 20, 2021

presented the. Biogazelle, an innovative bioanalytical services company offering RNA and. Ghent University Hospital for SARS-CoV-2 virus screening. study RNA virus replication and virus-host interactions and in particular the use of single-cell proteomics to aid in this research. samples per day.

Laboratories 52

Laboratories Virus RNA Bioinformatics 52

New Drug Approvals

SEPTEMBER 6, 2024

TLR7-9 are among the set that are endosomally located and respond to single-stranded RNA (TLR7and TLR8) or unmethylated single-stranded DNA containing cytosine-phosphate-guanine (CpG) motifs (TLR9). Toll/IL-1 receptor family members are important regulators of inflammation and host resistance. Nature Immunol., 11:373-384 (2010)).

RNA 62

RNA Clinical Trials DNA Disease 62

The Pharma Data

MARCH 20, 2021

Coronaviruses are RNA viruses and include common human coronaviruses, severe acute respiratory syndrome-CoV (SARS-CoV), Middle East respiratory syndrome-CoV (MERS-CoV) and SARS-CoV-2 ( 1 ). Detection of virus-specific antibodies allows for diagnosis of recent symptomatic or even asymptomatic infections. INTRODUCTION.

Virus 52

Virus Assay Development Laboratories RNA 52

The Pharma Data

JUNE 25, 2021

The outcome confirms that only one single case was attributable to the original SARS-CoV-2 virus. “In addition, the variant-rich environment underlines the importance of developing next-generation vaccines as new virus variants continue to emerge.” More than half of the cases (57%) were caused by Variants of Concern.

Vaccine 52

Vaccine Trials Immune Response Virus 52

Drug Target Review

SEPTEMBER 28, 2023

For security reasons, at the time COVID-19 had to be grown in BSL-3 labs, which can be dangerous because they were handling the live virus. These are synthetic, not the live virus, so do not pose a risk of infection. Researchers were able to use our synthetic RNA controls as a reference to verify and validate assays.

DNA 116

DNA Organic Chemistry Science Virus 116

The Pharma Data

JANUARY 21, 2021

Food and Drug Administration (FDA) has approved CABENUVA (consisting of Janssen’s rilpivirine and ViiV Healthcare’s cabotegravir), the first and only once-monthly, long-acting regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults. 50 c/mL, meeting noninferiority criteria.

FDA Approval 52

FDA Approval Treatment RNA FDA 52

Drug Target Review

JULY 11, 2023

Thus, when it is discovered that the same antibodies circling in these resilient individuals, that are not present in the group of individuals with a normal disease trajectory and are not present in healthy controls, it means that the body must selecting for it.

Disease 75

Disease RNA Small Molecule Clinical Development 75

Advarra

MARCH 31, 2023

This trend came to the forefront during the COVID-19 pandemic, as the three most popular vaccines developed in response to the coronavirus contained engineered genetic materials in the form of mRNA or a genetically engineered virus. Either way, occupational exposure to these gene delivery systems bears potential risks to the research staff.

Engineering 52

Engineering Clinical Research Research Virus 52

DrugBank

JANUARY 29, 2025

These disorders, often characterized by a loss-of-function mutation in a crucial gene, can manifest with a wide range of clinical presentations, depending on the specific gene and its role in cellular physiology. The system comprises a guide RNA that targets a specific DNA locus and the Cas9 enzyme that cleaves the DNA at the target site.

Therapies 52

Therapies DNA RNA Disease 52

Codon

JULY 27, 2023

“The first printout of the human genome to be presented as a series of books, displayed in the 'Medicine Now' room at the Wellcome Collection, London. Because it turns out that at least half of them , in humans, also bind to RNA molecules. How do transcription factors couple up with the correct RNA molecule? No longer.

Therapies 52

Therapies RNA DNA Engineering 52

Codon

JULY 27, 2023

“The first printout of the human genome to be presented as a series of books, displayed in the 'Medicine Now' room at the Wellcome Collection, London. Because it turns out that at least half of them , in humans, also bind to RNA molecules. How do transcription factors couple up with the correct RNA molecule? No longer.

Therapies 52

Therapies RNA DNA Engineering 52

Codon

MAY 30, 2023

The researchers first compared the editing efficiency of different versions of IscB when coupled with 'ωRNA,' which guides the enzyme to the right spot on the DNA. A particular variant, named IscB*-ωRNA*, had the highest editing efficiency across multiple different sites in the genome. Read more in Nature Methods.

DNA 52

DNA RNA Engineering Vaccine 52

Codon

MAY 30, 2023

The researchers first compared the editing efficiency of different versions of IscB when coupled with 'ωRNA,' which guides the enzyme to the right spot on the DNA. A particular variant, named IscB*-ωRNA*, had the highest editing efficiency across multiple different sites in the genome. Read more in Nature Methods.

DNA 52

DNA RNA Engineering Vaccine 52

The Pharma Data

DECEMBER 10, 2020

In the study, immunization with the hAd5-COVID-19 vaccine inhibited SARS-CoV-2 virus replication in 100% (10 of 10) of Rhesus macaques, with a drop in viral replication starting on the first day of vaccine administration, and undetectable viral levels as early as three to five days post-challenge in most of the animals.

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

Codon

APRIL 2, 2023

Read A new DNA polymerase variant, called RT-KTq I614Y, can directly detect RNA modifications, including pseudouridine (Ψ) and queuosine (Q). By combining this new variant with standard sequencing methods, it’s possible to identify RNA modifications in a really simple way. Nucleic Acids Research. Communications Biology.

DNA 52

DNA RNA Engineering Licensing 52

The Pharma Data

APRIL 22, 2023

Nasdaq: GILD) today announced positive results from several COVID-19 clinical and real-world evidence studies being presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). Antivirals play a key role in halting the replication of the SARS-CoV-2 virus.

Hospitals 40

Hospitals Treatment Virus Pharmacokinetics 40

The Pharma Data

JANUARY 22, 2021

As research developments into RNA vaccines help scientists accelerate drug candidates to arm the immune system against coronavirus, Pharma IQ ’s Keeping tabs on Covid-19 update returns with news from some of the biotechnology innovators leading the fight against the global pandemic.

Vaccine 52

Vaccine Immune Response Government RNA 52

The Pharma Data

OCTOBER 21, 2020

These findings were presented today at the 2020 Infectious Diseases Society of America (IDSA) IDWeek. Participants identified as impacted by COVID-19 will continue to be followed and data collected from that group is expected to be presented at a future medical meeting. Kimberly Smith, M.D., About ViiV Healthcare.

Clinical Development 52

Clinical Development Therapies Clinical Trials Treatment 52

The Pharma Data

DECEMBER 5, 2020

The first of the new therapies, developed at Harvard Medical School by a team led by Dr. David Williams, uses a virus to introduce RNA into the extracted bone marrow that turns off BCL11A. The German study is also scheduled for presentation on Saturday at the American Society of Hematology’s virtual annual meeting.

Therapies 52

Therapies Disease Medical Schools Virus 52

The Pharma Data

SEPTEMBER 1, 2020

This can help healthcare professionals identify a SARS-CoV-2 infection in people suspected to carry the virus with results typically ready in 15 minutes. The SARS-CoV-2 Rapid Antigen Test is for use in point of care settings for both symptomatic and asymptomatic people.

Virus 52

Virus Laboratories Clinical Trials Treatment 52